Tuesday 21 May, 2024 04:16 AM
Site map | Locate Us | Login
   Phoenix Mills Q4 PAT climbs 32% YoY to Rs 388 cr    Trident Q4 PAT soars 56% YoY; board OKs Rs 500-cr via NCDs    India Cements Q4 net loss narrows to Rs 50.06 cr    Parag Milk posts 56% YoY fall in Q4 PAT; EBITDA margin at 5.6%    Ujjivan SFB Q4 PAT rises 6% YoY; NII climbs 27% YoY to Rs 934 crore    Rainbow Medicare Q4 PAT slides to Rs 51 cr; ARPOB at Rs 54,185    Lupin?s USA facility gets 6 USFDA observations    Kirloskar Ferrous Q4 PAT drops 81% YoY to Rs 18 cr    ZEEL reports turnaround Q4 numbers    NHPC Q4 PAT slides 18% to Rs 610 cr    Nestle India ends higher after public shareholders reject royalty hike proposal to Swiss parent    Sobha Q4 PAT drops 85% YoY to Rs 7 cr    Kirloskar Ferrous Industries Ltd leads losers in 'A' group    Vindhya Telelinks Ltd leads losers in 'B' group    Volumes soar at MTAR Technologies Ltd counter 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Granules India gains after receiving US FDA nod for gout medicine
30-Apr-24   13:20 Hrs IST

The ANDA for Colchicine Capsules was filed by the company?s wholly owned foreign subsidiary Granules Pharmaceuticals, Inc. (GPI).

The approved drug is a bioequivalent and therapeutically equivalent to the reference listed drug (RLD) Mitigare Capsules of Hikma International Pharmaceuticals LLC (Hikma).

Colchicine Capsules are indicated for prophylaxis of gout flares in adults.

The current annual U.S. market for Colchicine Capsules is approximately $55 Million, according to MAT Feb 2024, IQVIA/IMS Health.

Granules now have a total of 64 ANDA approvals from the US FDA (63 Final approvals and 1 tentative approvals),? the company said in a statement.

Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs).

The pharma company's consolidated net profit rose 1.06% to Rs 125.65 crore on 0.82% increase in revenue from operations to Rs 1,155.58 crore in Q3 FY24 over Q3 FY23.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Span Margin | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures |Rights & Obligations-English| Rights & Obligations-தமிழ் | Anti Money Laundering Policy | E-Voting | CSR Hit Count : 32729649
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd